Published in Blood on October 20, 2010
IMWG consensus on risk stratification in multiple myeloma. Leukemia (2013) 2.28
Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol (2012) 2.25
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia (2011) 1.77
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood (2012) 1.56
Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia (2012) 1.35
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood (2016) 1.06
Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol (2013) 1.04
Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. Blood (2015) 1.01
Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma. Haematologica (2011) 1.01
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia (2013) 1.00
Many multiple myelomas: making more of the molecular mayhem. Hematology Am Soc Hematol Educ Program (2011) 1.00
Epigenetic modulating agents as a new therapeutic approach in multiple myeloma. Cancers (Basel) (2013) 0.97
The genetic architecture of multiple myeloma. Adv Hematol (2014) 0.96
Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma. Oncol Lett (2014) 0.89
GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target. Blood Cancer J (2014) 0.88
Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03. Br J Haematol (2011) 0.83
Implications of heterogeneity in multiple myeloma. Biomed Res Int (2014) 0.82
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? Blood (2015) 0.81
Staging and prognostication of multiple myeloma. Expert Rev Hematol (2014) 0.81
Multiple Myeloma, Version 2.2016. J Natl Compr Canc Netw (2015) 0.81
Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol (2016) 0.81
Defining and treating high-risk multiple myeloma. Leukemia (2015) 0.80
RE-IIBP Methylates H3K79 and Induces MEIS1-mediated Apoptosis via H2BK120 Ubiquitination by RNF20. Sci Rep (2015) 0.80
Genetic markers used for risk stratification in multiple myeloma. Genet Res Int (2011) 0.79
Prognostic value and efficacy evaluation of novel drugs for cytogenetic aberrations in multiple myeloma: a meta-analysis. Int J Clin Exp Med (2014) 0.78
t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs. Blood Cancer J (2015) 0.77
The RAG Model: A New Paradigm for Genetic Risk Stratification in Multiple Myeloma. Bone Marrow Res (2014) 0.77
Targeting the IGF-1R signaling and mechanisms for epigenetic gene silencing in human multiple myeloma. Ups J Med Sci (2012) 0.77
Inactivation of BANK1 in a novel IGH-associated translocation t(4;14)(q24;q32) suggests a tumor suppressor role in B-cell lymphoma. Blood Cancer J (2014) 0.76
Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. Biol Blood Marrow Transplant (2016) 0.75
MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma. Blood (2016) 0.75
The Evolution of Prognostic Factors in Multiple Myeloma. Adv Hematol (2017) 0.75
Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p). Oncotarget (2017) 0.75
Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion. Mod Pathol (2017) 0.75
Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma. Exp Hematol Oncol (2017) 0.75
Combination of t(4;14), del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myeloma. Mol Cytogenet (2017) 0.75
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med (2002) 8.86
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol (2010) 8.80
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med (2007) 8.77
Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med (2003) 7.35
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med (2014) 5.98
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med (2007) 5.84
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 5.80
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol (2011) 5.67
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood (2007) 5.55
Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med (2004) 5.36
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood (2006) 4.61
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood (2006) 4.40
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.30
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood (2006) 3.84
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol (2007) 3.54
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood (2003) 3.37
The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica (2007) 3.23
Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol (2009) 3.21
Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis (2008) 3.18
Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol (2010) 3.09
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood (2010) 3.06
First human face allograft: early report. Lancet (2006) 3.01
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Proteasome inhibitors in multiple myeloma: 10 years later. Blood (2012) 2.77
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol (2010) 2.75